Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting

被引：0
|
作者：
Shanshan Hu
Yilai Wu
Jiajie Luan
Shuowen Wang
Guorong Fan
机构：
[1] Shanghai General Hospital,Department of Clinical Pharmacy
[2] Shanghai Jiao Tong University School of Medicine,Department of Pharmacy
[3] The First Affiliated Hospital of Wannan Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Cost–utility analysis; HER2-positive metastatic breast; Trastuzumab deruxtecan; Trastuzumab emtansine; Price exploring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：17933 / 17942
页数：9
相关论文
共 50 条
  • [11] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
    Guan, X.
    Li, H-C.
    Chen, Q-J.
    Hua, B.
    Li, J-J.
    Ma, F.
    Wang, Y-S.
    Xu, H.
    Liu, C.
    Yang, Q.
    Ma, A-X.
    ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
  • [12] Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
    Cortes, J.
    Kim, S. -B
    Chung, W. -P
    Im, S. -A
    Park, Y. H.
    Hegg, R.
    Kim, M. H.
    Tseng, L. -M
    Petry, V
    Chung, C. -F
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Huang, C. -S
    Kim, J. H.
    Chiu, J. W. Y.
    Pedrini, J. L.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Verma, S.
    Hurvitz, S. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1143 - 1154
  • [13] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [14] Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
    Hurvitz, S. A.
    Kim, S. -B.
    Chung, W. -P.
    Im, S. -A.
    Park, Y. H.
    Hegg, R.
    Kim, M. -H.
    Tseng, L. -M.
    Petry, V.
    Chung, C. -F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Egorov, A.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Tecson, K.
    Verma, S.
    Cortes, J.
    ESMO OPEN, 2024, 9 (05)
  • [15] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [16] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
    Guan, X.
    Li, H. C.
    Xia, Y.
    Yang, Q.
    Ma, A. X.
    VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
  • [17] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [18] Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1425): : 75 - 76
  • [19] Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci, Francesco
    Le Tourneau, Christophe
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (01)
  • [20] COST-UTILITY ANALYSIS OF TRASTUZUMAB IN TREATMENT OF METASTATIC HER2-POSITIVE BREAST CANCER IN VIETNAM
    Nguyen, T. T. C.
    Nguyen, T. T. T.
    VALUE IN HEALTH, 2014, 17 (07) : A643 - A643
12345